Abpro Holdings shares surge 11.07% intraday following FDA clearance of ABP-102/CT-P72 for Phase 1 trials.

Abpro Holdings surged 11.07% intraday after announcing FDA clearance for its lead oncology program ABP-102/CT-P72 on January 6, 2026. The regulatory milestone enables Phase 1 trials to evaluate safety and efficacy in HER2-positive tumors, with preclinical data highlighting potential in resistant cancer models. The collaboration with Celltrion for global development further underscores the program’s strategic value. This clearance represents a critical advancement for the company’s pipeline, likely driving investor optimism about therapeutic differentiation and commercial potential in oncology.